<p>Your are about to enter the australian website of the B. Braun Group. We recommend you visit the website of your local B. Braun organization.</p>

United States - B. Braun Medical Inc.

Australia - B. Braun Australia Pty. Ltd

<p>Not all products are registered and approved for sale in all countries or regions. Indications of use also may vary by country and region. Please contact your country representative for product availability and information. Product images are for reference only.</p>

Cancel

You have successfully logged out.

AMI Feasibility Study

SeQuent® Please (NEO) vs. DES (SES) in de novo lesions

Drug-coated balloon versus drug-eluting stent in primary percutaneous coronary intervention: a feasibility study

_{Gobić D et al. Am. J. Med. Sci. 2017; 354(6): 553-60}

Medical Professional

This information is meant for medical professionals only. Please confirm that you are a medical professional before accessing the information.

Confirm Yes, I am a health care professional. Cancel No, I am not a health care professional.

Key findings

DCB angioplasty with SeQuent® Please and SeQuent® Please NEO is safe and feasible in patients with acute myocardial infarction with ST elevation.
The MACE rate was low in the DCB group with no events between the 1- and 6-month follow-up. The angiographic follow-up showed significantly smaller LLL in the DCB group than in the DES group. In the DCB group LLL was negative, meaning that patients experienced on average Late Lumen Gain.

Description

Design: Randomized | Open-label | Prospective | Single center

Indication: De novo

Main patient inclusion criterion: STEMI (< 12 h)

Endpoints:

MACE @ 6-month follow-up. Components of MACE: Cardiac death, Re-infarction, TLR and Stent thrombosis
LLL @ 6-month follow-up

DAPT: 12 months

Results

Patients: In total, 78 patients were enrolled in this trial. 37 patients were randomized into the DES group and 41 patients in the DCB group. Three patients in the DCB group required bailout stenting and were further excluded from the study.

Baseline characteristics: The two treatment groups were well balanced, there were no statistically significant differences between the groups.

Endpoints:

	DCB n = 38	DES n = 37	p-value
MACE @ 1-month follow-up	5.3 %	5.4 %	0.98
MACE @ 6-month follow-up (additional events after 1-month follow-up)	0 %	5.4 %	0.24
LLL	- 0.09 ± 0.09 mm	0.10 ± 0.19 mm	< 0.05

Further information on PubMed

Get in touch with our Coronary Drug Coated Balloon experts

Coronary Drug Coated Balloon contact form